McKesson Corporation (MCK) Analysts See $2.89 EPS

January 14, 2018 - By Marguerite Chambers

 McKesson Corporation (MCK) Analysts See $2.89 EPS
Investors sentiment decreased to 0.88 in 2017 Q3. Its down 0.07, from 0.95 in 2017Q2. It is negative, as 65 investors sold McKesson Corporation shares while 296 reduced holdings. 72 funds opened positions while 246 raised stakes. 180.04 million shares or 2.23% more from 176.11 million shares in 2017Q2 were reported.
Horan Advsrs Limited Liability Co holds 140 shares or 0.01% of its portfolio. North Tide Cap Ltd Co reported 500,000 shares. Bancorporation Of Nova Scotia Tru invested 0.01% of its portfolio in McKesson Corporation (NYSE:MCK). Segall Bryant And Hamill Limited reported 2,200 shares. Brown Advisory invested 0% in McKesson Corporation (NYSE:MCK). Dean Ltd Liability Company has 0.55% invested in McKesson Corporation (NYSE:MCK). Sector Gamma As, a Norway-based fund reported 119,100 shares. Ingalls Snyder Ltd Liability Corp reported 16,939 shares. Royal Savings Bank Of Scotland Public Ltd Com reported 0.2% in McKesson Corporation (NYSE:MCK). First Foundation owns 0.02% invested in McKesson Corporation (NYSE:MCK) for 1,924 shares. Martingale Asset Mgmt Lp holds 0.09% in McKesson Corporation (NYSE:MCK) or 41,416 shares. Great Lakes Advsr Limited Liability holds 1.13% or 313,354 shares in its portfolio. Old Mutual Customised Solutions (Proprietary) Ltd holds 0.15% or 7,015 shares. Moreover, Hgk Asset Inc has 1.85% invested in McKesson Corporation (NYSE:MCK) for 84,737 shares. Boston Private Wealth Ltd Llc has 7,146 shares.

Since August 21, 2017, it had 0 insider purchases, and 6 selling transactions for $121.83 million activity. JACOBS M CHRISTINE sold $157,500 worth of stock or 1,083 shares. Another trade for 300,000 shares valued at $46.43 million was sold by HAMMERGREN JOHN H.

Analysts expect McKesson Corporation (NYSE:MCK) to report $2.89 EPS on January, 24.They anticipate $0.14 EPS change or 4.62 % from last quarter’s $3.03 EPS. MCK’s profit would be $602.49 million giving it 14.38 P/E if the $2.89 EPS is correct. After having $3.28 EPS previously, McKesson Corporation’s analysts see -11.89 % EPS growth. The stock increased 2.43% or $3.95 during the last trading session, reaching $166.25. About 1.84M shares traded. McKesson Corporation (NYSE:MCK) has declined 15.45% since January 14, 2017 and is downtrending. It has underperformed by 32.15% the S&P500.

McKesson Corporation (NYSE:MCK) Ratings Coverage

Among 22 analysts covering McKesson Corporation (NYSE:MCK), 11 have Buy rating, 1 Sell and 10 Hold. Therefore 50% are positive. McKesson Corporation has $275 highest and $130.0 lowest target. $189.60’s average target is 14.05% above currents $166.25 stock price. McKesson Corporation had 73 analyst reports since July 31, 2015 according to SRatingsIntel. Mizuho maintained it with “Buy” rating and $275 target in Monday, September 21 report. The firm has “Overweight” rating by Barclays Capital given on Friday, April 28. Mizuho maintained the shares of MCK in report on Tuesday, October 27 with “Buy” rating. On Thursday, January 5 the stock rating was downgraded by JP Morgan to “Neutral”. The stock of McKesson Corporation (NYSE:MCK) earned “Neutral” rating by Mizuho on Thursday, August 11. Credit Suisse downgraded McKesson Corporation (NYSE:MCK) on Wednesday, November 23 to “Underperform” rating. Robert W. Baird maintained the stock with “Buy” rating in Thursday, October 26 report. The firm has “Hold” rating by Leerink Swann given on Monday, April 24. On Tuesday, August 9 the stock rating was maintained by JP Morgan with “Overweight”. RBC Capital Markets maintained the shares of MCK in report on Tuesday, January 12 with “Outperform” rating.

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. The company has market cap of $34.66 billion. The firm operates in two divisions, McKesson Distribution Solutions and McKesson Technology Solutions. It has a 7.87 P/E ratio. The McKesson Distribution Solutions segment distributes branded and generic pharmaceutical drugs, and other healthcare-related products; and provides practice management, technology, clinical support, and business solutions to community oncology and other specialty practices.

More recent McKesson Corporation (NYSE:MCK) news were published by: Sacbee.com which released: “It’s California’s second richest company, but you probably haven’t heard of it” on January 11, 2018. Also Investorplace.com published the news titled: “Opioid Crisis: McKesson Corporation Stock Drops After 60 Minutes Report” on December 18, 2017. Seekingalpha.com‘s news article titled: “McKesson: Is This Pharmaceutical Distributor A Buy?” with publication date: December 31, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.